Development of a machine learning-based multimode diagnosis system for lung cancer.

Journal: Aging
Published Date:

Abstract

As an emerging technology, artificial intelligence has been applied to identify various physical disorders. Here, we developed a three-layer diagnosis system for lung cancer, in which three machine learning approaches including decision tree C5.0, artificial neural network (ANN) and support vector machine (SVM) were involved. The area under the curve (AUC) was employed to evaluate their decision powers. In the first layer, the AUCs of C5.0, ANN and SVM were 0.676, 0.736 and 0.640, ANN was better than C5.0 and SVM. In the second layer, ANN was similar with SVM but superior to C5.0 supported by the AUCs of 0.804, 0.889 and 0.825. Much higher AUCs of 0.908, 0.910 and 0.849 were identified in the third layer, where the highest sensitivity of 94.12% was found in C5.0. These data proposed a three-layer diagnosis system for lung cancer: ANN was used as a broad-spectrum screening subsystem basing on 14 epidemiological data and clinical symptoms, which was firstly adopted to screen high-risk groups; then, combining with additional 5 tumor biomarkers, ANN was used as an auxiliary diagnosis subsystem to determine the suspected lung cancer patients; C5.0 was finally employed to confirm lung cancer patients basing on 22 CT nodule-based radiomic features.

Authors

  • Shuyin Duan
    College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
  • Huimin Cao
    College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
  • Hong Liu
    Key Laboratory of Grain and Oil Processing and Food Safety of Sichuan Province, College of Food and Bioengineering, Xihua University Chengdu 610039 China xingyage1@163.com.
  • Lijun Miao
    The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, China.
  • Jing Wang
    Endoscopy Center, Peking University Cancer Hospital and Institute, Beijing, China.
  • Xiaolei Zhou
    Henan Provincial Chest Hospital, Zhengzhou 450001, China.
  • Wei Wang
    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China.
  • Pingzhao Hu
    c Department of Biochemistry and Medical Genetics , University of Manitoba , Winnipeg , MB , Canada.
  • Lingbo Qu
    College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
  • Yongjun Wu
    Department of Health Toxicology, College of Public Health, Zhengzhou University, Zhengzhou, China. wuyongjun@zzu.edu.cn.